Home  |  Contact

UniProtKB/Swiss-Prot Q9BQB6: Variant p.Tyr139His

Vitamin K epoxide reductase complex subunit 1
Gene: VKORC1
Variant information

Variant position:  139
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Tyrosine (Y) to Histidine (H) at position 139 (Y139H, p.Tyr139His).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from large size and aromatic (Y) to medium size and polar (H)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In CMRES.
Any additional useful information about the variant.



Sequence information

Variant position:  139
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  163
The length of the canonical sequence.

Location on the sequence:   YLAWILFFVLYDFCIVCITT  Y AINVSLMWLSFRKVQEPQGK
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         YLAWILFFVLYDFCIVCITTYAINVSLMWLSFRKVQEPQGK

Mouse                         YLAWILFFVLYDFCIVCITTYAINVGLMLLSFQKV--PEHK

Rat                           YLAWILFFVLYDFCIVCITTYAINAGLMLLSFQKV--PEHK

Bovine                        YLAWILFFVLYDFCIVCITTYAINVGLTVLSFREVQGPQGK

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 163 Vitamin K epoxide reductase complex subunit 1
Transmembrane 127 – 149 Helical
Alternative sequence 59 – 163 WGRGFGLVEHVLGQDSILNQSNSIFGCIFYTLQLLLGCLRTRWASVLMLLSSLVSLAGSVYLAWILFFVLYDFCIVCITTYAINVSLMWLSFRKVQEPQGKAKRH -> LPADTLGLCPDAAELPGVSRWFCLPGLDPVLRAL. In isoform 3.
Alternative sequence 95 – 163 GCLRTRWASVLMLLSSLVSLAGSVYLAWILFFVLYDFCIVCITTYAINVSLMWLSFRKVQEPQGKAKRH -> DGVSPCCPGWSQAICLPQPPKVLGGLQALPADTLGLCPDAAELPGVSRWFCLPGLDPVLRAL. In isoform 2.
Mutagenesis 120 – 120 L -> Q. Decreases enzyme activity moderately. Decreases inhibition by warfarin.
Mutagenesis 128 – 128 L -> QS. Decreases enzyme activity by about 80%. Decreases inhibition by warfarin.
Mutagenesis 132 – 132 C -> S. Nearly abolishes enzyme activity.
Mutagenesis 135 – 135 C -> S. Nearly abolishes enzyme activity.
Mutagenesis 139 – 139 Y -> CGS. Decreases enzyme activity moderately. Strongly decreases inhibition by warfarin.
Mutagenesis 139 – 139 Y -> F. No effect on enzyme activity. Strongly decreases inhibition by warfarin.


Literature citations

Thirteen novel VKORC1 mutations associated with oral anticoagulant resistance: insights into improved patient diagnosis and treatment.
Watzka M.; Geisen C.; Bevans C.G.; Sittinger K.; Spohn G.; Rost S.; Seifried E.; Muller C.R.; Oldenburg J.;
J. Thromb. Haemost. 9:109-118(2011)
Cited for: VARIANTS CMRES THR-26; LEU-29; GLY-36; TYR-36; TRP-52; PHE-56; LEU-59; CYS-59; GLY-66; MET-66; ALA-71; SER-77; TYR-77; ASN-123 AND HIS-139;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.